United Therapeutics Plunges 2.19% on $200M Volume Ranks 448th Amid Institutional and Insider Selling

On August 25, 2025, United Therapeutics (UTHR) closed with a 2.19% decline, trading a volume of $200 million and ranking 448th in market activity. The stock faces pressure from recent institutional and insider selling activity, despite maintaining a "Moderate Buy" analyst consensus.

Institutional investors adjusted holdings in the first quarter, with Northern Trust Corp reducing its stake by 3.6% to 471,365 shares, while Hohimer Wealth Management and Applied Finance Capital Management increased positions by 0.3% and 3.7% respectively. Dunhill Financial LLC doubled its holdings in the fourth quarter, and 94.08% of shares remain under institutional ownership. These mixed adjustments reflect ongoing strategic reallocations among major investors.

Insider activity intensified in recent months, with CFO James Edgemond slashing his ownership by 59.65% through a $3.9 million share sale and Director Richard Giltner reducing his stake by 13.54%. Total insider sales over 90 days reached $28 million, raising questions about management’s confidence in near-term valuation. Despite this, analysts remain cautiously optimistic, with HC Wainwright setting a $400 price target and UBS Group boosting its target to $415, while Morgan Stanley trimmed its objective to $328.

A backtest of a volume-based trading strategy (buying top 500 stocks by daily trading volume and holding for one day) showed a 31.52% total return from 2022 to 2025, with a 0.98% average daily gain. The strategy peaked at 7.02% in June 2023 but declined -4.65% in September 2022, highlighting its volatility. While not directly applicable to UTHR, the results underscore market momentum dynamics influencing short-term performance.